Last reviewed · How we verify
Aerosolized, Recombinant Alpha 1-Antitrypsin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Aerosolized, Recombinant Alpha 1-Antitrypsin (Aerosolized, Recombinant Alpha 1-Antitrypsin) — Baxalta now part of Shire.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Aerosolized, Recombinant Alpha 1-Antitrypsin TARGET | Aerosolized, Recombinant Alpha 1-Antitrypsin | Baxalta now part of Shire | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Aerosolized, Recombinant Alpha 1-Antitrypsin CI watch — RSS
- Aerosolized, Recombinant Alpha 1-Antitrypsin CI watch — Atom
- Aerosolized, Recombinant Alpha 1-Antitrypsin CI watch — JSON
- Aerosolized, Recombinant Alpha 1-Antitrypsin alone — RSS
Cite this brief
Drug Landscape (2026). Aerosolized, Recombinant Alpha 1-Antitrypsin — Competitive Intelligence Brief. https://druglandscape.com/ci/aerosolized-recombinant-alpha-1-antitrypsin. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab